RaQualia Pharma Inc. announced a private placement of 625,000 shares at an issue price of Ã1,258 for the gross proceeds of Ã786,250,000, 12,500 16th stock acquisition rights at an issue price of Ã1,549 for the gross proceeds of Ã19,362,500; aggregate proceeds of Ã805,612,500 on December 20, 2022. The transaction will include participation from CVI Investments, Inc. for 625,000 shares. The transaction has been approved by the board of directors of the company.
The common shares and 16th stock acquisition rights is expected to close on January 5, 2023.